The DOI matches its Crossref record; 201 of the 203 references it cites were found in a registry or an index.
STAT3, a Master Regulator of Anti-Tumor Immune Response
Open accessAbstract
Immune cells in the tumor microenvironment regulate cancer growth. Thus cancer progression is dependent on the activation or repression of transcription programs involved in the proliferation/activation of lymphoid and myeloid cells. One of the main transcription factors involved in many of these pathways is the signal transducer and activator of transcription 3 (STAT3). In this review we will focus on the role of STAT3 and its regulation, e.g., by phosphorylation or acetylation in immune cells and how it might impact immune cell function and tumor progression. Moreover, we will review the ability of STAT3 to regulate checkpoint inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IL-6 is also a key factor in inflammation, autoimmunity and cancer, with its effect mainly exerted through the IL-6–signal transducer and activator of transcription 3 (STAT3) pathway (18–26, 61–65).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, NF-κB and STAT3 play crucial roles in cancer development and progression (19, 25, 67, 279).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibitors against the IL-6–STAT3 signaling pathway are under development (19, 21, 24–26, 76, 374).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Much evidence has accumulated to show that STAT3 functions as an inhibitor for DC differentiation, maturation and antigen-presenting ability, and therefore STAT3 inhibits tumor immunity by interfering with DC functions (Fig. 2) (25).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“MDSC function is dependent on STAT3 (25).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Chen, W., Jin, W., Hardegen, N. J., Lei, K.-J., Li, L., Marinos, N. J., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,678
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,659
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,455
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023
Flagged first, then by citations
2 of the 203 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–130 of 130
Identification of PECAM1 as a Prognostic Biomarker for Lung Adenocarcinoma
Lin, S.-S., Hsu, P.-S., Lin, Y.-C., You, J., Shih, Y.-L., & Lai, H.-C. (2025) · Diagnostics · doi:10.3390/diagnostics15091094 · Cited by 2
The concurrent silencing of Tim-3 and STAT-3 promotes tumor regression both in vitro and in ovo
Karami, R., Khodayari, S., Eshaghi, F. S., Ebrahimi, F., Khodakarami, A., Rashidi, B., Nikdel, M., Mehr, H. M., Kazemi, T., & Jadidi‐Niaragh, F. (2025) · BMC Cancer · doi:10.1186/s12885-025-14830-5 · Cited by 2
Qin, Y.-G., Mao, Z.-C., Chen, L., Ma, X., Wei, J.-H., Huang, R.-Z., & Zhang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109274 · Cited by 2
Chen, H., Fu, R., & Wu, Z. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01877-8 · Cited by 3
Gagliardi, M., Kean, R. B., Dai, B., Augustine, J. J., Roberts, M., Fleming, J. B., Hooper, D. C., & Ashizawa, A. T. (2024) · Biomedicines · doi:10.3390/biomedicines12081901 · Cited by 2
Feasibility of the inhibitor development for cancer: A systematic approach for drug design
Jiang, Y., Liu, L., Geng, Y., Li, Q., Luo, D., Liang, L., Liu, W., Ouyang, W., & Hu, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306632 · Cited by 2
Białas, P., Kobayashi, T., Hellsten, R., Krzyzanowska, A., Persson, M., Marginean, F. E., Trudel, D., Garraway, I. P., Trock, B. J., Taimen, P., et al. (2024) · The Prostate · doi:10.1002/pros.24820 · Cited by 1
Pan, D., Zhang, C., Wang, Y., Liu, S., & Wu, X.-Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1619186 · Cited by 1
Wedharga, I. G. P. A., Willianto, V. M., Theodora, I., Parengkuan, I. L., & Novita, B. D. (2025) · INDONESIAN JOURNAL OF MEDICAL LABORATORY SCIENCE AND TECHNOLOGY · doi:10.33086/ijmlst.v7i2.7711 · Cited by 1
Yao, Y., Zhang, M., Xu, S., Wu, G., Meng, X., Li, J., & Yu, H. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126989 · Cited by 2
Recent progress of PROTACs in cancer immunotherapy
Liu, P., Chen, Q., & Li, J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110042 · Cited by 1
Zhang, Y., Lu, T., Liu, K., Zhang, B., & 徐澍 (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1811985 · Cited by 1
Correlation between Nod-like Receptor Protein 3 Inflammasome and Diabetic Dry Eye
Zhao, X., & Zhang, R. (2022) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.590 · Cited by 1
Venkatraman, S., Balasubramanian, B., Kongpracha, P., Yangngam, S., Chuangchot, N., Khanaruksombat, S., Thongchot, S., Suntiparpluacha, M., Myint, K. Z., Soodvilai, S., et al. (2024) · Cancers · doi:10.3390/cancers16244197 · Cited by 1
Jia, B., Wang, X., Ma, F., Li, X., Han, X., Zhang, L., Li, J., Diao, N.-C., Shi, K., Chen-xia, G., et al. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.1042445 · Cited by 1
Investigating epigenetic therapies and combinations for the treatment of cancers
O’Brien, S. W. (2023) · Digital Repository Service (Northeastern University) · doi:10.17760/d20620610 · Cited by 1
[Review] The Landscape of Interferons in Health and DiseasePreprint
Brown, B., Imarogbe, C., & Fricke, I. (2024) · Qeios · doi:10.32388/pbxuf5.2 · Cited by 1
Albosale, A. H. (2021) · RESEARCH RESULTS IN BIOMEDICINE · doi:10.18413/2658-6533-2021-7-2-0-2
A comparative study of the PRF mediated cellular reaction of tumour cells
Parkhoo, K. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.87557
Cutaneous toxicities secondary to STAT3 inhibition: A retrospective case series
Lee, K. P., Tsimberidou, A. M., Chakraborty, A., & Patel, A. B. (2025) · JAAD Case Reports · doi:10.1016/j.jdcr.2025.03.027
A Multi-Layered Atlas of Spatial Regulatory Programs and Therapeutic Vulnerabilities in GlioblastomaPreprint
Zhang, L., Lu, M., Ma, X., & Osmanbeyoglu, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.27.674707
Yousef, B. A., Elhafiz, M., Ahmedani, E. I., Ismail, M., Bahafi, A. A., El‐Moselhy, M. A., & Saleh, M. A. (2025) · Oriental Journal Of Chemistry · doi:10.13005/ojc/410609
Redundant roles of YES and SRC tyrosine kinases in driving malignant peripheral nerve sheath tumorsPreprint
Zereg, E., Voisin, L., Courcelles, M., Brochu, S., Gombos, M., Bonneil, É., Grenier, K., Jung, S., Perreault, C., Tirode, F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.17.706384
Liu, Y., Li, S., Li, W., Zhou, M., Liang, J., Liu, X., Wang, X. Y., Guo, Y., Li, Z., Zhang, B., et al. (2026) · Carcinogenesis · doi:10.1093/carcin/bgag026
Shen, S. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2676080
Šútovská, M., Dohál, M., Gondáš, E., Mažerik, J., Švihra, J., Cipková, L., Fraňová, S., & Ľupták, J. (2026) · Cancers · doi:10.3390/cancers18121972
Schepisi, G., Torresan, I., Giunta, E. F., Bleve, S., Brighi, N., Tassinari, E., Zanuccoli, S., Cursano, M. C., & Lolli, C. (2026) · The Journal of Pathology · doi:10.1002/path.70095
Ibrahim, D., Khater, S. I., Abdelfattah‐Hassan, A., Babteen, N. A., Alqahtani, L. S., Qahl, S. H., Mostafa, M., El-Shaer, N. O., Abdel-Raheem, S. M., Alkhayyal, N., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1963760
Liu, Z., He, Y., Fang, T., Zhang, Y., Mou, Z., Ma, P., Yu, K., & Wang, W. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.155048
Metadata
- Authors
- Rébé, C., & Ghiringhelli, F.
- Affiliations
- Inserm (FR)
- Corresponding author
- Rébé, Cédric
- Ghiringhelli, François
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-08-30
- Volume
- 11
- Issue
- 9
- Pages
- 1280
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6770459
- OpenAlex
- W2970221585
- Cited by
- 129
- References
- 203
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 29 · 2023: 17 · 2022: 14 · 2021: 13 · 2020: 16 · 2019: 5
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ligue Contre le Cancer (Equipe labélisée)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- STAT3, tumor immune microenvironment, antitumor immunity, transcription factors, immune cell activation, myeloid cells, lymphoid cells, STAT3 phosphorylation, STAT3 acetylation, immune checkpoint, tumor progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
